Return to homepagePandemic Pact

To develop anti-viral COVID-19 therapeutics based on direct targeting of the viral RNA genome using LNA anti-sense oligonucleotides.

  • Funded by Emergent Ventures Fast Grants
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Emergent Ventures Fast Grants

  • Principal Investigator

    Dr. Anders Näär

  • Research Location

    United States of America

  • Lead Research Institution

    University of California-Berkeley

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

To develop anti-viral COVID-19 therapeutics based on direct targeting of the viral RNA genome using LNA anti-sense oligonucleotides.